IP Verse

Anti-Dll3 Antibody - EP2530091

The patent EP2530091 was granted to Chugai Seiyaku Kabushiki Kaisha on Apr 4, 2018. The application was originally filed on Jan 28, 2011 under application number EP11736812A. The patent is currently recorded with a legal status of "Revoked".

EP2530091

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP11736812A
Filing Date
Jan 28, 2011
Status
Revoked
Jun 26, 2024
Grant Date
Apr 4, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ABBVIEJan 4, 2019KONIG SZYNKA TILMANN VON RENESSE DUSSELDORFADMISSIBLE
ABBVIEJan 4, 2019KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
BOEHRINGER INGELHEIM RCV BOEHRINGER INGELHEIMJan 2, 2019HOFFMANN EITLEADMISSIBLE
SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBJan 2, 2019UEXKULL & STOLBERGADMISSIBLE

Patent Citations (36) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0239400
DESCRIPTIONEP0404097
DESCRIPTIONJP2010019391
DESCRIPTIONJPS6459878
DESCRIPTIONWO0061739
DESCRIPTIONWO02079255
DESCRIPTIONWO0231140
DESCRIPTIONWO03104453
DESCRIPTIONWO2005017155
DESCRIPTIONWO2008093688
DESCRIPTIONWO9203918
DESCRIPTIONWO9311161
DESCRIPTIONWO9312227
DESCRIPTIONWO9402602
DESCRIPTIONWO9411523
DESCRIPTIONWO9425585
DESCRIPTIONWO9602576
DESCRIPTIONWO9954342
INTERNATIONAL-SEARCH-REPORTWO2007080597
INTERNATIONAL-SEARCH-REPORTWO2007111733
INTERNATIONAL-SEARCH-REPORTWO2008047925
INTERNATIONAL-SEARCH-REPORTWO2009124931
OPPOSITIONJP2008273973
OPPOSITIONJPH11299493
OPPOSITIONWO0047602
OPPOSITIONWO0112664
OPPOSITIONWO0175067
OPPOSITIONWO0214358
OPPOSITIONWO03025138
OPPOSITIONWO2004030615
OPPOSITIONWO2004053102
OPPOSITIONWO2005077090
OPPOSITIONWO2007080597
OPPOSITIONWO2007111733
OPPOSITIONWO2009124931
SEARCHWO2007111733

Non-Patent Literature (NPL) Citations (35) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anti-Delta3, clone 1E7.2, (20080715), URL: http://www.millipore.com/catalogue/item/MABT189?cid=bios-a-antr-1012-1206, XP002697359-
OPPOSITION- GODING, J.W., "7 Introduction to M onoclonal Antibodies", GODING, J.W., Goding, Monoclonal Antibodies: Principles and Practice third edition, pages 134 - 135, XP055549225-
OPPOSITION- "Human DLL3 Antibody Monoclonal Mouse IgG2B Clone #378703", (20100505), URL: http://www.rndsystems.com/pdf/MAB4315.pdf, XP002697358-
OPPOSITION- "Immunoglobulin G", Review InvivoGen, (20110000), XP055055390-
OPPOSITION- "Mechanisms of Antibody-Based Tumor Immunity", ZANETTI, M. et al., The Antibodies volume 6, Harwood academic, vol. 6, pages 36 - 37, XP055549209-
OPPOSITION- "Monoclonal Anti-h uman DLL3 Antibody", R&D Systems, (20050914), XP055549202-
OPPOSITION- "Monoclonal Anti-human DLL3 Antibody", R&D SYSTEMS Product sheet, (20070517), XP055544564-
OPPOSITION- "Press Releases. Compugen Announces Discovery of Blood Based Biomarker for Diagnosis of Lung Cancer", Compugen, (20080429), URL: https://www.cgen.com/mediacenter/compugen-announces-discovery-of-blood-based-biomarker-for-diagnosis-of-lung-cancer/, XP055549330-
OPPOSITION- SUN et al., "Antibody-drug conjugates as targeted cancer therapeutics", Acta Pharmaceutica Sinica, (20090000), vol. 44, no. 9, pages 943 - 952, XP055549246-
OPPOSITION- GRANT et al., "Targeting of small- cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial", European Journal of Nuclear Medicine, (19960200), vol. 23, pages 145 - 149, XP055549261
OPPOSITION- DUNWOODIE, "The role of notch in patterning the human vertebral column", Current Opinion in Genetics & Development, (20090000), vol. 19, pages 329 - 337, XP026499467
OPPOSITION- NIMMERJAHN et al., "Fc(gamma) receptors: Old friends and new family members", Immunity, (20060000), vol. 24, pages 19 - 28, XP002498113
OPPOSITION- CHUNG et al., "Characterization of in vitro antibody-dependent cell - mediated cytotoxicity activity of therapeutic antibodies - Impact of effector cells", Journal of Immunological Methods, (20140000), vol. 407, pages 63 - 75, XP029030119
OPPOSITION- HENKE et al., "Ascl1 and Neurog2 form novel complexes and regulate delta-like3 (DII3) expression in the neural tube", NIH Public Access Author Manuscript, (20090000), vol. 328, no. 2, pages 1 - 24, XP055549306
OPPOSITION- BALL, "Achaete-scute homolog-1 and notch in lung neuroendocrine development and cancer", Cancer Letters, (20040000), vol. 204, pages 159 - 169, XP055549315
OPPOSITION- ADAMS et al., "Monoclonal antibody therapy of cancer", Nature Biotechnology, (20050000), vol. 23, pages 1147 - 1157, XP002456710
OPPOSITION- D'SOUZA et al., "The many facets of notch ligands", Oncogene, (20080000), vol. 27, pages 5148 - 5167, XP055549266
OPPOSITION- AYYANAN et al., "Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism", PNAS USA, (20060000), vol. 103, no. 10, pages 3799 - 3804, XP008167483
OPPOSITION- SHIELDS et al., "High resolution mapping of the binding site on human IgG1 for Fc(gamma)RI, Fc(gamma)RII, Fc(gamma)RIII, and FcRn and design of IgG1 variants with improved binding to the Fc(gamma)R", J. Biol. Chem., (20010000), vol. 276, no. 9, pages 6591 - 6604, XP002271092
OPPOSITION- CHOI et al., "Distinct biological roles for the notch ligands jagged-1 andjagged-2", The Journal of Biological Chemistry, (20090000), vol. 284, no. 26, pages 17766 - 17774, XP055549320
OPPOSITION- LADI et al., "The divergent DSL ligand DLL3 does not activate notch signaling but cell autonomously attenuates signaling induced by other DSL ligands", The Journal of Cell Biology, (20050000), vol. 170, no. 6, pages 983 - 992, XP055549301
OPPOSITION- GEFFERS et al., "Divergent functions and distinct localization of the notch ligands DLL 1 and DLL3 in vivo", The Journal of Cell Biology, (20070000), vol. 178, no. 3, pages 465 - 476, XP055549269
OPPOSITION- Carter et al., "Antibody-drug conjugates for cancer therapy", The Cancer Journal, vol. 14, no. 3, pages 154 - 169, XP055549236
OPPOSITION- JIANG et al., "Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung Cancer", Cancer Res., (20090000), vol. 69, no. 3, pages 845 - 854, XP002697824
OPPOSITION- JIANG et al., "Achaete-scute complex homologue 1 regulates tumor- initiating capacity in human small cell lung cancer", Cancer Research, (20090000), vol. 69, no. 3, pages 845 - 854, XP002697824
OPPOSITION- MULLENDORE et al., "Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer", Clin Cancer Res, (20090000), vol. 15, no. 7, pages 2291 - 2301, XP055544557
OPPOSITION- TANEJA et al., "Markers of small cell lung cancer", World Journal of Surgical Oncology, (20040000), vol. 2, no. 10, pages 1 - 5, XP055549336
OPPOSITION- WENG et al., "Two immunoglobulin G fragment C receptor polymorphisms ind ependently predict response to rituximab in patients with follicular lymphoma", Journal of Clinical Oncology, (20030000), vol. 21, no. 21, pages 3940 - 3947, XP003013385
OPPOSITION- SHITARA, "Potelligent antibodies as next generation therapeutic antibodies", (20090000), vol. 129, no. 1, pages 3 - 9, XP055549341
OPPOSITION- STOCKWIN et al., "ANTIBODIES AS THERAPEUTIC AGENTS: VIVE LA RENAISSANCE!", Expert Opin. Biol. Ther., (20030000), vol. 3, no. 7, pages 1133 - 1152, XP008050055
OPPOSITION- CHEN et al., "Antibody-cytotoxic agent conjugates for cancer therapy", Expert Opinion in Drug Delivery, (20050000), vol. 2, no. 5, pages 873 - 890, XP008060439
OPPOSITION- CARTER et al., "Identification and validation of cell surface antigens for antibody targeting in oncology", Endocrine-Related Cancer, (20040000), vol. 11, pages 659 - 687, XP009078100
SEARCH- MILLIPORE, "Anti-Delta3, clone 1E7.2", INTERNET CITATION, (20080715), pages 1 - 3, URL: http://www.millipore.com/catalogue/item/MABT189?cid=bios-a-antr-1012-1206, (20130514), XP002697359 [X] 1,7 * the whole document * [I] 6-
SEARCH- R&D SYSTEMS, "Human DLL3 Antibody Monoclonal Mouse IgG2B Clone # 378703, Catalog Number: MAB4315", INTERNET CITATION, (20100505), page 1, URL: http://www.rndsystems.com/pdf/MAB4315.pdf, (20120518), XP002697358 [IP] 1,7 * the whole document *-
SEARCH- JIANG TIANYUN ET AL, "Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung Cancer", CANCER RESEARCH, (200902), vol. 69, no. 3, ISSN 0008-5472, pages 845 - 854, XP002697824 [I] 12 * page 847, column 2, line l - page 848, column 1, paragraph 2 * * table 1 * * figure 2 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents